MDLN vs MRK
Medline Inc. vs Merck & Co. — AI-powered side-by-side comparison
MDLN
Medline Inc.
51
Watch
VS
| Metric | MDLN | MRK |
|---|
| AI Score |
51
|
70
|
| Price |
$35.02
|
$130.34
|
| P/E Ratio |
40.74×
|
103.53×
|
| ROE |
10.8%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
25.0%
|
75.4%
|
| Debt / Equity |
1.09×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
37.7
|
64.5
|
| Beta |
-0.4106
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MDLN versus MRK.
MRK leads by 19 points.
MRK scores 70/100 (Buy) versus MDLN at 51/100 (Watch).
MDLN Committee View
40% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 64.1 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 64.1 is expensive by classic value standards — Value
- Price-to-book of 5.0x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical